Seeking Alpha

Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely...

Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|